Enovis Corp (ENOV) — SEC Filings
Enovis Corp (ENOV) — 32 SEC filings. Latest: 8-K (May 7, 2026). Includes 15 8-K, 7 SC 13G/A, 6 10-Q.
Overview
Enovis Corp (ENOV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 10, 2025: On December 8, 2025, Enovis Corporation entered into a material definitive agreement related to a direct financial obligation. The company, formerly known as Colfax Corp, is incorporated in Delaware and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral. The dominant filing sentiment for Enovis Corp is neutral.
Filing Type Overview
Enovis Corp (ENOV) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 7 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ENOV's 22 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,672,291,000 |
| Net Income | $-663,851,000 |
| EPS | $-11.64 |
| Cash Position | $33,600,000 |
Key Executives
- Steven R. Smith
Industry Context
Enovis operates in the medical technology sector, specifically focusing on orthopedics and related healthcare solutions. The industry is characterized by innovation, regulatory oversight, and consolidation through mergers and acquisitions. Companies like Enovis compete by developing advanced products, building strong distribution networks, and demonstrating clinical efficacy. Trends include an aging population driving demand for orthopedic solutions and increasing adoption of minimally invasive procedures.
Top Tags
corporate-governance (6) · executive-compensation (5) · 10-Q (4) · financials (4) · board-of-directors (3) · 8-K (3) · financial-statements (3) · amendment (3) · institutional-ownership (3) · Orthopedics (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss attributable to Enovis Corporation | $571.1M | for the three months ended October 3, 2025, significantly higher than $31.5 million in the prior year |
| Goodwill impairment charge | $548.4M | for the three and nine months ended October 3, 2025, a primary driver of the net loss |
| Net sales | $548.9M | for the three months ended October 3, 2025, an 8.6% increase from $505.2 million in the prior year |
| Net loss per share - basic and diluted | $9.99 | for continuing operations for the three months ended October 3, 2025, compared to $0.61 in the prior year |
| Consideration for Dr Comfort Sale | $60M | upfront payment of $45 million and up to $15 million contingent |
| Loss on held for sale net assets | $7.6M | recognized for the Dr Comfort divestiture |
| Total consideration for 2025 acquisitions | $37.7M | including $7.6 million in Q2 and $30.1 million in Q1 |
| Cash and cash equivalents | $33.6M | as of October 3, 2025, a decrease from $48.2 million at December 31, 2024 |
| Shares of common stock outstanding | 57,189,381 | as of October 31, 2025 |
| Q2 2025 Revenue | $420.5M | Increased 9.2% from $385.2M in Q2 2024, indicating strong market demand. |
| Q2 2025 Net Income | $35.8M | Grew 27.4% from $28.1M in Q2 2024, showcasing enhanced profitability. |
| Q2 2025 Diluted EPS | $0.65 | Up from $0.52 in Q2 2024, reflecting improved earnings per share for investors. |
| Revenue Growth | 9.2% | Percentage increase in revenue from Q2 2024 to Q2 2025, demonstrating business expansion. |
| Net Income Growth | 27.4% | Percentage increase in net income from Q2 2024 to Q2 2025, highlighting operational efficiency. |
| Reporting Period | Q1 2025 | First quarter of 2025 financial performance |
Forward-Looking Statements
- {"claim":"Enovis Corporation's stock price may experience downward pressure in the short term.","entity":"Enovis Corporation","targetDate":"3 months","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in Enovis Corporation.","entity":"institutional investors","targetDate":"6 months","confidence":"medium"}
- {"claim":"Dimensional Fund Advisors LP will likely maintain its passive stake in Enovis Corp for the foreseeable future.","entity":"Dimensional Fund Advisors LP","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Enovis Corp (ENOV)?
Enovis Corp has 32 recent SEC filings from Jan 2024 to May 2026, including 15 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ENOV filings?
Across 32 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral. The dominant sentiment is neutral.
Where can I find Enovis Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Enovis Corp (ENOV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Enovis Corp?
Key financial highlights from Enovis Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ENOV?
The investment thesis for ENOV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Enovis Corp?
Key executives identified across Enovis Corp's filings include Steven R. Smith.
What are the main risk factors for Enovis Corp stock?
Of ENOV's 22 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Enovis Corp?
Recent forward-looking statements from Enovis Corp include guidance on {"claim":"Enovis Corporation's stock price may experience downward pressure in the short term.","entity":"Enovis Corpora and 2 other predictions.